MSD MIRROR tool briefing materials: Appeal Board overturns product-claim breaches but upholds high-standards failures (AUTH/2699/2/14)

📊

Key facts

⌄

Case number	AUTH/2699/2/14
Parties	Anonymous (non-contactable health professional) v Merck Sharp & Dohme
Products	Ezetrol (ezetimibe); Januvia (sitagliptin)
Activity	Use of MIRROR tool (interactive database using NHS HES data) and associated briefing/launch materials
Complaint received	3 February 2014
Case completed	8 July 2014
Applicable Code	2012 (second edition)
Allegation theme	Implied outcome claims/off-label implications when linking admissions data to product promotion; disguised promotion alleged
Final outcome (Appeal Board)	No breach for alleged product-claim clauses; breach upheld for internal briefing materials and high standards
No breach clauses	2, 3.1, 3.2, 7.2, 7.4, 7.5, 7.10, 12.1
Breach clauses	9.1, 15.9
Sanctions	Undertaking received

Reviewed by Dr Anzal Qurbain (FFPM) — ABPI Final Signatory

🤖

Got a question about this case?

Ask one of our 13 specialist ABPI advisors — instant answers, 24/7.

Ask AskAnzal AI

🎬 Expert Video Walkthrough

🎬

Video walkthrough — coming for members

Subscribe now and get expert video analysis for every case as we publish them.

Subscribe — from £299/yr

📋

⌄

An anonymous, non-contactable clinician (with a CCG advisory role) complained about a meeting with two Merck Sharp & Dohme (MSD) representatives using a computer programme called MIRROR (an interactive database using NHS Health Episode Statistics data).
The complainant alleged MIRROR was used to discuss non-elective hospital admissions (coronary events and hypoglycaemia-related admissions) and then to imply MSD medicines could reduce those admissions.
Allegations included that Ezetrol (ezetimibe) was presented as stopping coronary events and Januvia (sitagliptin) as stopping hypoglycaemic events requiring hospital treatment—without outcome data.
MSD denied the allegations, stated MIRROR users were trained, and said it could not identify any such meeting in its CRM records. MSD provided screenshots and briefing/training materials but could not provide the full tool due to its interactive nature.
Panel (first instance) initially ruled multiple breaches relating to implied outcome benefits and off-label promotion, plus high standards and discredit.
Appeal: MSD argued the meeting likely did not occur as described and that the complaint lacked supporting evidence (eg, no generated report was provided). MSD also clarified that MIRROR was used by Area Access Leads (AALs), typically alone, and that a two-disease-area MIRROR session would be impractically long.

⚖️

⌄

Appeal Board: Not satisfied the alleged meeting took place (on the balance of probabilities). Therefore, it ruled no breaches in relation to the alleged product claims about Ezetrol and Januvia.
However, the Appeal Board upheld that the MIRROR tool briefing/launch materials were likely to encourage discussions linking products to MIRROR-generated data in a way that could lead to Code breaches.
Breach upheld: Clause 15.9 (briefing materials advocated a course of action likely to lead to a breach).
Breach upheld: Clause 9.1 (high standards not maintained).
Clause 2 (discredit) was not upheld on appeal.

🔒

Members get the complete breakdown — Clauses, Sanction, Signatory Lens, Audit checklist, and 3 Key Questions.

Best value

£249/year

Annual — save £99

£29/mo

Monthly

Join Now — Instant Access